Serum CA 19‐9 in the postsurgical follow‐up of patients with pancreatic cancer

75Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the last few years serum CA 19‐9 has been shown to be a highly sensitive marker of pancreatic adenocarcinoma. This study assesses the value of serum CA 19‐9 assay in the postsurgical follow‐up of patients undergoing pancreatic cancer resection. In 14 patients with cancer in the head of the pancreas and abnormal preoperative serum CA 19‐9 values (>40 U/ml), a pancreatoduodenectomy was performed. In all patients the CA 19‐9 antigen was immunohistochemically demonstrated on the removed tumoral tissue. Postoperative serum CA 19‐9 concentrations were serially measured 15 days after surgery and then every other month. Serum CA 19‐9 scores returned to the normal range only in 7 (50%) of the resected patients. All patients with a normal postoperative value and none of those with a persistently elevated one survived longer than 7 months. Early postoperative serum CA 19‐9 assay was superior to perioperative staging of the tumor as a prognostic index. All of the seven patients with postoperative normal values exhibited a subsequent increase within 16 months. In all cases the elevation of CA 19‐9 occurred at least 2 months before ultrasound (US) could detect local recurrences of hepatic metastasis. Our data indicate that a normal early postoperative CA 19‐9 score is a relatively favourable prognostic index in patients who undergo radical surgery for pancreatic cancer and that the CA 19‐9 test can be used, as an early marker of recurrence, in monitoring these patients. Copyright © 1987 American Cancer Society

References Powered by Scopus

Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9

505Citations
N/AReaders
Get full text

Collective review of small carcinomas of the pancreas

346Citations
N/AReaders
Get full text

Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank

198Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer

571Citations
N/AReaders
Get full text

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704

327Citations
N/AReaders
Get full text

Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population

307Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Beretta, E., Malesci, A., Zerbi, A., Mariani, A., Carlucci, M., Bonato, C., … Carlo, V. D. (1987). Serum CA 19‐9 in the postsurgical follow‐up of patients with pancreatic cancer. Cancer, 60(10), 2428–2431. https://doi.org/10.1002/1097-0142(19871115)60:10<2428::AID-CNCR2820601013>3.0.CO;2-O

Readers over time

‘11‘12‘15‘16‘17‘18‘19‘20‘21‘2202468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

75%

Professor / Associate Prof. 2

17%

Researcher 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

75%

Agricultural and Biological Sciences 1

8%

Social Sciences 1

8%

Chemistry 1

8%

Save time finding and organizing research with Mendeley

Sign up for free
0